Moderate

Periprocedural anticoagulant & antiplatelet management

Bridging decisions · Cardiac
Physician-written · Verified by three sets of doctors · Reviewed November 2026

Bedside summary

Managing antithrombotics around procedures balances thromboembolic risk against procedural bleeding. Most patients on DOACs do not need bridging, while a minority on warfarin with high thrombotic risk do; decisions are individualised by drug, renal function and bleeding risk.

Red flags

  • Mechanical mitral valve (high thrombotic risk)
  • Thromboembolic event within the preceding 3 months
  • Recent coronary stent within the DAPT window
  • Major bleeding during or after the procedure
  • Antiphospholipid syndrome with prior thrombosis

Assessment

Differential diagnosis

  • Atrial fibrillation on anticoagulation
  • Mechanical heart valve
  • Recent venous thromboembolism
  • Recent coronary stent on DAPT
  • Antiphospholipid syndrome
  • Prior thromboembolism on warfarin

Investigations

  • Renal function (to time DOAC interruption)
  • INR for warfarin patients
  • FBC for baseline haemoglobin/platelets
  • Assessment of procedural bleeding risk
  • Review of indication and thrombotic risk
  • Liver function where relevant

Management

  • Determine whether the procedure can proceed without stopping anticoagulation (minor/low-bleed procedures)
  • Classify the patient's thrombotic risk and procedural bleeding risk
  • For DOACs, stop based on drug, renal function and bleeding risk (commonly 24-48 h before)
  • Do not routinely bridge DOAC patients — their offset is predictable
  • For warfarin, stop ~5 days before and check INR before the procedure
  • Bridge warfarin with LMWH only in high-thrombotic-risk patients (mechanical mitral valve, recent VTE/stroke)
  • Avoid bridging low/moderate-risk AF patients on warfarin (increases bleeding)
  • Plan the timing of restarting anticoagulation based on haemostasis and bleeding risk
  • For recent coronary stents, delay elective surgery and continue aspirin where possible
  • Coordinate antiplatelet interruption with the implanting cardiologist
  • Give clear written restart instructions
  • Document the plan and communicate with all teams

Drugs & doses

Resume DOAC (e.g. apixaban 5 mg PO BD) once haemostasis secured
Enoxaparin 1 mg/kg SC BD for high-risk warfarin bridging (last dose timed before surgery)
Warfarin restart on the evening of or day after the procedure
Continue aspirin 75-100 mg PO OD perioperatively in most stented patients
Reduced prophylactic LMWH dose for moderate-risk bridging where used

Disposition

Preoperative/anticoagulation clinic planning; cardiology input for mechanical valves, recent stents or complex thrombotic risk.

Complications & pitfalls

  • Perioperative thromboembolism
  • Procedural or postoperative bleeding
  • Stent thrombosis from premature antiplatelet cessation
  • Heparin-induced thrombocytopenia (with bridging)
  • Delayed anticoagulation restart

Exam pearls

  • BRIDGE trial showed no benefit and more bleeding from routine warfarin bridging in AF
  • DOACs rarely need bridging — interruption timing depends on renal function
  • Many minor procedures can continue on anticoagulation
  • Resume full-dose anticoagulation cautiously after high-bleed-risk surgery
  • Mechanical valves and very recent VTE are the main indications to bridge

Disclaimer: Educational decision support for qualified clinicians and students — not a substitute for clinical judgement, local protocols or a full drug reference. Confirm every dose and contraindication against your formulary before prescribing.